Compare · NTRA vs OSCR
NTRA vs OSCR
Side-by-side comparison of Natera Inc. (NTRA) and Oscar Health Inc. (OSCR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRA and OSCR operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $30.84B, about 4.2x OSCR ($7.39B).
- Over the past year, NTRA is up 31.2% and OSCR is up 66.1% - OSCR leads by 34.8 points.
- NTRA has been more active in the news (16 items in the past 4 weeks vs 11 for OSCR).
- Both have 25 recent analyst ratings on file.
- Company
- Natera Inc.
- Oscar Health Inc.
- Price
- $215.31-3.06%
- $24.50+3.90%
- Market cap
- $30.84B
- $7.39B
- 1M return
- +0.14%
- +23.70%
- 1Y return
- +31.25%
- +66.08%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- 2021
- News (4w)
- 16
- 11
- Recent ratings
- 25
- 25
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Oscar Health Inc.
Oscar Health, Inc. provides health insurance products and services in the United States. The company offers Individual & Family, Small Group, and Medicare Advantage plans, as well as +Oscar, a full stack technology platform. It also provides reinsurance products. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was founded in 2012 and is headquartered in New York, New York.
Latest NTRA
- CEO AND PRESIDENT Chapman Steven Leonard sold $9,089,776 worth of shares (41,124 units at $221.03) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 108,743 units (SEC Form 4)
- Natera Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $655,295 worth of shares (3,000 units at $218.43) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 137,643 units (SEC Form 4)
- Director Rubin Eric H was granted 2,124 shares, increasing direct ownership by 42,480% to 2,129 units (SEC Form 4)
- Director Botha Roelof sold $17,184,092 worth of shares (78,000 units at $220.31) (SEC Form 4)
- Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
- Wolfe Research resumed coverage on Natera with a new price target
- SEC Form 144 filed by Natera Inc.
- Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
Latest OSCR
- Chief Accounting Officer Baltrus Victoria sold $33,417 worth of shares (1,523 units at $21.94) as part of a pre-agreed trading plan, decreasing direct ownership by 0.70% to 214,589 units (SEC Form 4) to satisfy tax liability
- Director Schlosser Mario sold $748,633 worth of shares (34,120 units at $21.94) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 480,866 units (SEC Form 4) to cover withholding tax
- Chief Legal Officer Mcananey Adam sold $216,318 worth of shares (9,859 units at $21.94) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 218,096 units (SEC Form 4) (tax withholding)
- President, Oscar Insurance Liang Janet sold $273,716 worth of shares (12,475 units at $21.94) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 259,057 units (SEC Form 4) (tax withholding)
- Chief Financial Officer Blackley Richard Scott sold $695,162 worth of shares (31,683 units at $21.94) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,074,977 units (SEC Form 4) (tax withholding)
- Oscar Health upgraded by Wells Fargo with a new price target
- SEC Form 144 filed by Oscar Health Inc.
- Oscar Health Inc. filed SEC Form 8-K: Leadership Update
- Chief Financial Officer Blackley Richard Scott sold $2,753,300 worth of shares (110,000 units at $25.03) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 1,106,660 units (SEC Form 4)
- SEC Form 144 filed by Oscar Health Inc.